Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1983 Oct;46(10):929–935. doi: 10.1136/jnnp.46.10.929

Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

S M Aquilonius, S A Eckernäs, P Hartvig, B Lindström, P O Osterman, E Stålberg
PMCID: PMC1027607  PMID: 6644317

Abstract

Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with determination of the plasma concentrations following administration of pyridostigmine or neostigmine. In these patients the existence of a "bell-shaped" dose response curve is suggested with the maximal effect at a concentration of 30-60 ng/ml for pyridostigmine and 5-15 ng/ml for neostigmine.

Full text

PDF
929

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aquilonius S. M., Eckernäs S. A., Hartvig P., Hultman J., Lindström B., Osterman P. O. A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry. Eur J Clin Pharmacol. 1979 Jun 12;15(5):367–371. doi: 10.1007/BF00558442. [DOI] [PubMed] [Google Scholar]
  2. Aquilonius S. M., Eckernäs S. A., Hartvig P., Lindström B., Osterman P. O. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol. 1980 Nov;18(5):423–428. doi: 10.1007/BF00636797. [DOI] [PubMed] [Google Scholar]
  3. Brown R. D., Manno J. E. ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1978 Dec;67(12):1687–1691. doi: 10.1002/jps.2600671214. [DOI] [PubMed] [Google Scholar]
  4. Calvey T. N., Chan K. Plasma pyridostigmine levels in patients with myasthenia gravis. Clin Pharmacol Ther. 1977 Feb;21(2):187–193. doi: 10.1002/cpt1977212187. [DOI] [PubMed] [Google Scholar]
  5. Chan K., Calvey T. N. Plasma concentration of pyridostigmine and effects in myastenia gravis. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):596–601. doi: 10.1002/cpt1977225part1596. [DOI] [PubMed] [Google Scholar]
  6. Chan K., Calvey T. N. Renal clearance of pyridostigmine in patients with myasthenia gravis. Eur Neurol. 1977;16(1-6):69–72. doi: 10.1159/000114882. [DOI] [PubMed] [Google Scholar]
  7. Chan K., Davison S. C., Dehghan A., Hyman N. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration. Methods Find Exp Clin Pharmacol. 1981 Sep-Oct;3(5):291–296. [PubMed] [Google Scholar]
  8. Chan K., Williams N. E., Baty J. D., Calvey T. N. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr. 1976 May 26;120(2):349–358. doi: 10.1016/s0021-9673(76)80012-x. [DOI] [PubMed] [Google Scholar]
  9. Cohan S. L., Pohlmann J. L., Mikszewski J., O'Doherty D. S. The pharmacokinetics of pyridostigmine. Neurology. 1976 Jun;26(6 Pt 1):536–539. doi: 10.1212/wnl.26.6.536. [DOI] [PubMed] [Google Scholar]
  10. Cronnelly R., Stanski D. R., Miller R. D., Sheiner L. B. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther. 1980 Jul;28(1):78–81. doi: 10.1038/clpt.1980.134. [DOI] [PubMed] [Google Scholar]
  11. Davison S. C., Hyman N. M., Dehghan A., Chan K. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry. 1981 Dec;44(12):1141–1145. doi: 10.1136/jnnp.44.12.1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kornfeld P., Samuels A. J., Wolf R. L., Osserman K. E. Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites. Neurology. 1970 Jul;20(7):634–641. doi: 10.1212/wnl.20.7.634. [DOI] [PubMed] [Google Scholar]
  13. OOSTERHUIS H. J. STUDIES IN MYASTHENIA GRAVIS. 1. A CLINICAL STUDY OF 180 PATIENTS. J Neurol Sci. 1964 Nov-Dec;1(6):512–546. doi: 10.1016/0022-510x(64)90171-6. [DOI] [PubMed] [Google Scholar]
  14. Stålberg E., Trontelj J. V., Schwartz M. S. Single-muscle-fiber recording of the jitter phenomenon in patients with myasthenia gravis and in members of their families. Ann N Y Acad Sci. 1976;274:189–202. doi: 10.1111/j.1749-6632.1976.tb47685.x. [DOI] [PubMed] [Google Scholar]
  15. White M. C., De Silva P., Havard C. W. Plasma pyridostigmine levels in myasthenia gravis. Neurology. 1981 Feb;31(2):145–150. doi: 10.1212/wnl.31.2.145. [DOI] [PubMed] [Google Scholar]
  16. Williams N. E., Calvey T. N., Chan K. Clearance of neostigmine from the circulation during the antagonism of neuromuscular block. Br J Anaesth. 1978 Oct;50(10):1065–1067. doi: 10.1093/bja/50.10.1065. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES